Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Roivant SciencesROIV -1.47%51 Days Sales Outstanding is 0.00 as of Jun. 2026. GuruFocus rates ROIV with a GF Score™ of 51/100 and a GF Value™ of $6.31 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 835 Biotechnology companies, Roivant Sciences ranks worse than 119760.36% on this metric.
The historical rank and industry rank for Roivant Sciences's Days Sales Outstanding or its related term are showing as below:
During the past 6 years, Roivant Sciences's highest Days Sales Outstanding was 338.96. The lowest was 25.60. And the median was 198.28.
ROIV's Days Sales Outstanding is not ranked *
in the Biotechnology industry.
Industry Median: 68.95 * Ranked among companies with meaningful Days Sales Outstanding only.
Roivant Sciences's Days Sales Outstanding
stayed the same
from Jun. 2025 (0.00) to Jun. 2026 (0.00).
Roivant Sciences (NAS:ROIV) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Roivant Sciences Days Sales Outstanding Related Terms
Roivant Sciences Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Roivant Sciences's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROIV vs RPRX, INCY, INSM: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Roivant Sciences's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Roivant Sciences Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Roivant Sciences's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Roivant Sciences's Days Sales Outstanding falls into.
Roivant Sciences Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Roivant Sciences (ROIV) has a Days Sales Outstanding of 0.00 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Roivant Sciences and its competitors. Over the past decade, Roivant Sciences' Days Sales Outstanding has ranged from 25.60 to 338.96. According to the industry distribution chart, Roivant Sciences ranks #999999 out of 835 companies in the Biotechnology industry.
Is Roivant Sciences' Days Sales Outstanding too high?
Roivant Sciences' current Days Sales Outstanding is 0.00. Over the past 10 years, this metric has ranged from a low of 25.60 to a high of 338.96. Based on the distribution chart, Roivant Sciences ranks #999999 out of 835 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Roivant Sciences has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roivant Sciences' Days Sales Outstanding compare to RPRX and INCY?
According to the Biotechnology industry distribution chart, Roivant Sciences ranks #999999 out of 835 companies for Days Sales Outstanding. This places Roivant Sciences in the lower half of its industry. The industry median Days Sales Outstanding is 68.95. Historically, Roivant Sciences' own Days Sales Outstanding has ranged from 25.60 to 338.96 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.95, based on 835 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Roivant Sciences and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Roivant Sciences's current Days Sales Outstanding is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roivant Sciences stock overvalued right now?
Based on GuruFocus' analysis, Roivant Sciences (ROIV) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.31, compared to a current price of $36.30 — trading 475.3% above its estimated fair value. The current Days Sales Outstanding is 0.00. Roivant Sciences' overall GF Score™ is 51/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Roivant Sciences (ROIV), the current Days Sales Outstanding is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Roivant Sciences (ROIV) Overvalued in 2026?
Based on GuruFocus' analysis, Roivant Sciences stock appears to be overvalued.
The current stock price of $36.30 is trading 475.3% above its estimated GF Value™ of $6.31.
GuruFocus considers Roivant Sciences to be Significantly Overvalued.
Key valuation signals for ROIV:
Days Sales Outstanding: 0.00
GF Value™: $6.31 vs. price of $36.30 (475.3% above fair value)
No single metric tells the full story. See the ROIV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
51GF Score
Get the complete analysis for ROIV
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROIV has been successfully added to your 
